Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2026 strategic priorities across its cell therapy pipeline targeting autoimmune diseases. Descartes-08 Program Updates: Enrollment remains on track in the Phase 3 AURORA trial of Descartes-08, Cartesian’s autologous anti-B cell maturation antigen chimeric antigen receptor T-cell therapy, in participants with MG. Cartesian announced the U.S. Food and Drug Administration (FDA) accepted the investigational new drug application for its planned Phase 2 trial in myositis. Cartesian today announced the initiation of its Phase 1/2 pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including juvenile dermatomyositis. the Company announced the publication of two peer-reviewed journal articles in Nature Medicine detailing the mechanism of action of Descartes-08 as well as reiterating data surrounding the Phase 2b trial of Descartes-08 in patients with MG.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics announces employment inducement grants
- Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
- Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
- H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’
- Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating